Autologous Transplant To End NMO Spectrum Disorder

NCT03829566 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Discontinued by Investigator

Conditions

Neuromyelitis Optica
Devic's Disease
NMO Spectrum Disorder

Interventions

DRUG: Rituximab
DRUG: Cyclophosphamide
DRUG: Mesna
DRUG: rATG
DRUG: Methylprednisolone
DRUG: G-CSF
BIOLOGICAL: IVIg
BIOLOGICAL: Autologous Stem Cells

Sponsor

Northwestern University